Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562925 | 0.92 | CXCR2 (1.00) | CXCR2 | |
| Hydrochloric Acid SCHEMBL4355911 | 0.91 | CXCR2 (0.98) | CXCR2 | |
| Elubrixin SCHEMBL1663270 | 0.91 | CXCR2 (0.83) | CXCR2 | |
| SCHEMBL13629874 | 0.86 | CXCR2 (0.70) | CXCR2 | |
| SCHEMBL4162992 | 0.85 | CXCR2 (0.68) | CXCR2 | |
| SCHEMBL1562889 | 0.81 | CXCR2 (0.81) | CXCR2 | |
| SCHEMBL13096283 | 0.81 | CXCR2 (0.79) | CXCR2 | |
| Elubrixin SCHEMBL1562280 | 0.81 | CXCR2 (1.00) | CXCR2 | |
| Elubrixin SCHEMBL30515706 | 0.81 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL17293264 | 0.80 | CXCR2 (0.74) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | claimed |
| EP-2034832-A2 | IL-8 RECEPTOR ANTAGONIST | SmithKline Beecham Corporation (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007150016-A2 | IL-8 RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | CXCR2 2176/4885 |
| US-20090170871-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.